Becton Dickinson to name diabetes care spinoff 'embecta'

Becton Dickinson & Co. said Monday that the spinoff of its diabetes care business will be named "embecta." The previously announced spinoff, into an independent publicly traded company, is expected to be completed in the second quarter of 2022. Devdatt Kurdikar, who is president of the diabetes care business, will become chief executive officer of embecta. Becton Dickinson's stock, which was still inactive in premarket trading, has slipped 2.4% year to date, while the S&P 500 has rallied 20.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.